IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL5.12▼ 0.28% USD/MXN16.94▲ 0.16% USD/CLP914.28— 0.00% USD/COP3,038▼ 0.15% USD/PEN3.36▲ 0.05% USD/ARS1,499▼ 0.03% USD/UYU40.20▲ 1.52% USD/PYG5,996▲ 1.39% USD/BOB11.43▲ 0.51% USD/DOP58.61▼ 0.07% USD/CRC450.05▲ 1.95% USD/GTQ7.62▲ 2.13% USD/HNL26.81▲ 1.55% USD/NIO36.62— 0.00% USD/VES782.70▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.71▲ 0.82% EUR/BRL6.00▲ 0.03% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 24, 2026

Covid-19 Brazil

Brazilian man remained with coronavirus in his organism for 218 days

By · June 24, 2021 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – Last November, the case of a 45-year-old man attracted the attention of the scientific community. This patient, who was treated in a Boston hospital, had Sars-CoV-2 in his body for 154 days – and the virus suffered 66 mutations in his body.

Now, a group of researchers from USP, Sírio-Libanês and Nove de Julho hospitals, Imperial College London, and Oxford University reported a similar case, but with an even longer infection: a Brazilian man about 40 years old who had the coronavirus for 218 days.

Covid mystery. (Photo internet reproduction)
Covid mystery. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

Like the American patient, the Brazilian had a compromised immune system – because he had undergone treatment for lymphoma (cancer of the lymphatic system). The Brazilian researchers wrote a scientific article describing the case.

In September 2020, six months after cancer treatment, the patient has a fever, headache, and aching limbs. He visits a doctor and tests positive for Sars-CoV-2. He receives two antibiotics (used to control secondary bacterial pneumonia, manifest in lungs damaged by coronavirus) and goes home. However, his symptoms worsen, and he seeks hospitalization. At this point, his blood oxygen rate is only 87%.

The man improves and is discharged from the hospital at the end of the month. But a few days later, he has symptoms again – fatigue, chest pain, and difficulty breathing – and is hospitalized again. His condition worsened, and he was even intubated. Nevertheless, he recovers and is discharged from the hospital after three months.

A few days later, the symptoms return (fever and shortness of breath), and he is readmitted. By this time, the patient’s bout with Covid-19 is over four months old. The disease is on day 134, with coronavirus tests (performed on days 6, 77, and 128) always coming back positive. The case is followed with even greater attention – and the man undergoes Sars-CoV-2 tests on days 134, 141, 148, 155, 162, 169, 196, and 218. All indicate the presence of the virus. The man did not develop antibodies to the virus at any time.

The scientists genetically analyzed the samples of days 6, 77, 134, 168, and 196, all belonging to the lineage B.1.128, widely distributed in Brazil. Still, the virus accumulates mutations during the course of the disease: There are 13, of which 4 are “synonymous” (do not change the structure of the virus) and 9 are “nonsynonymous” (mutations that alter or eliminate amino acids of the virus, changing its structure and function).

The result is a unique variant that has arisen in the patient’s body. This phenomenon can pose an epidemiological risk: if the person transmits the virus to others (including doctors or nurses when they are in the hospital), they can introduce a new variant into society. However, in the case of the Brazilian patient, there is no evidence that this has happened.

Since the first mutations of Sars-CoV-2 appeared last year, patients with immunological impairments have been considered possible foci of the new variants. This is because the body cannot eliminate the virus in them, as it replicates over a long time, allowing mutations to accumulate.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.